Home › Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety...
 

Keywords :   


Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety...

2015-02-27 16:20:00| Appliances - Topix.net

CAMBRIDGE, Mass. & STOCKHOLM-- -- Biogen Idec and Swedish Orphan Biovitrum AB today announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of ALPROLIXA [Coagulation Factor IX , Fc Fusion Protein] in children under age 12 with severe hemophilia B. ALPROLIX was generally well tolerated and no inhibitors were detected during the study.

Tags: positive safety announce efficacy

Category:Consumer Goods and Services

Latest from this category

All news
17.05Union forming stalled in US Mercedes-Benz
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
17.05Register For Sustainable Cosmetics Summit
17.05Fewer crackers in Ritz boxes but price remains same
17.05Boeing boss's $33m pay package approved
17.05Urban Decay Renews Sponsorship Agreement with the Los Angeles Sparks
17.05Bank of England plans expansion of Leeds base
17.05Bank of England plans expansion of Leeds base
Consumer Goods and Services »
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
17.05House Republicans release farm bill draft
17.05House Republicans release farm bill draft
17.05Union forming stalled in US Mercedes-Benz
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
17.05Register For Sustainable Cosmetics Summit
17.05Fewer crackers in Ritz boxes but price remains same
More »